Literature DB >> 23948807

Risk of fracture in patients with muscular dystrophies.

S Pouwels1, A de Boer, H G M Leufkens, W E J Weber, C Cooper, H A W van Onzenoort, F de Vries.   

Abstract

UNLABELLED: The aim of the study was to determine fracture risk in incident muscular dystrophy (MD) patients. Patients with MD are at a 1.4-fold increased risk of fracture as compared with population-based control patients. Risk further increased among elderly and female patients and among patients exposed to oral glucocorticoids.
INTRODUCTION: Muscular dystrophies (MDs) are inherited diseases causing muscle weakness and thereby increase the risk of falling and detrimental effects on bone. Both are recognised risk factors for fracture. Therefore, the aim of this study was to determine the hazard ratio of fracture in patients with MD.
METHODS: We conducted a retrospective cohort study using the UK General Practice Research Database (1987-2012). Each patient with MD was matched by year of birth, sex and practice to up to six patients without a history of MD. Outcome measure was all fractures.
RESULTS: As compared with control patients, risk of any fracture was statistically significantly increased in MD patients (adjusted hazard ratio [AHR], 1.40; 95 % confidence interval [CI], 1.14-1.71). An increased risk of fracture was observed among MD patients with female gender (AHR, 1.78; 95 % CI, 1.33-2.40) and an increasing age as compared with control patients. Stratification to Duchenne MD showed no association with fracture, whereas risk of fracture was increased twofold among patients with myotonic dystrophy (AHR, 2.34; 95 % CI, 1.56-3.51). MD patients had an almost tripled risk of fracture when they used oral glucocorticoids in the previous 6 months as compared to non-users with MD.
CONCLUSION: Patients with MD are at a 1.4-fold increased risk of fracture as compared with population-based control patients. Especially in older age groups and female gender, the fracture risk of MD versus non-MD patients is increased, whereas exposure to glucocorticoids further increased fracture risk among MD patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23948807     DOI: 10.1007/s00198-013-2442-2

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  28 in total

1.  The UK General Practice Research Database.

Authors:  T Walley; A Mantgani
Journal:  Lancet       Date:  1997-10-11       Impact factor: 79.321

2.  Fractures in users of antidepressants and anxiolytics and sedatives: effects of age and dose.

Authors:  P Vestergaard; D Prieto-Alhambra; M K Javaid; C Cooper
Journal:  Osteoporos Int       Date:  2012-06-06       Impact factor: 4.507

Review 3.  Use of oral corticosteroids and risk of fractures.

Authors:  T P Van Staa; H G Leufkens; L Abenhaim; B Zhang; C Cooper
Journal:  J Bone Miner Res       Date:  2000-06       Impact factor: 6.741

Review 4.  The muscular dystrophies.

Authors:  Alan E H Emery
Journal:  Lancet       Date:  2002-02-23       Impact factor: 79.321

5.  Use of anti-depressants and the risk of fracture of the hip or femur.

Authors:  M W M van den Brand; S Pouwels; M M Samson; T P van Staa; B Thio; C Cooper; H G M Leufkens; A C G Egberts; H J J Verhaar; F de Vries
Journal:  Osteoporos Int       Date:  2009-02-24       Impact factor: 4.507

6.  Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy.

Authors:  W M King; R Ruttencutter; H N Nagaraja; V Matkovic; J Landoll; C Hoyle; J R Mendell; J T Kissel
Journal:  Neurology       Date:  2007-05-08       Impact factor: 9.910

7.  The outcome of depressive disorders in neurology patients: a prospective cohort study.

Authors:  A J Carson; K Postma; J Stone; C Warlow; M Sharpe
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-07       Impact factor: 10.154

Review 8.  Rehabilitation interventions for foot drop in neuromuscular disease.

Authors:  C Sackley; P B Disler; L Turner-Stokes; D T Wade
Journal:  Cochrane Database Syst Rev       Date:  2007-04-18

9.  The use of a large pharmacoepidemiological database to study exposure to oral corticosteroids and risk of fractures: validation of study population and results.

Authors:  T P Van Staa; L Abenhaim; C Cooper; B Zhang; H G Leufkens
Journal:  Pharmacoepidemiol Drug Saf       Date:  2000-09       Impact factor: 2.890

10.  An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus.

Authors:  A P Monaco; C J Bertelson; S Liechti-Gallati; H Moser; L M Kunkel
Journal:  Genomics       Date:  1988-01       Impact factor: 5.736

View more
  7 in total

1.  Effects of teriparatide on bone mineral density and quality of life in Duchenne muscular dystrophy related osteoporosis: a case report.

Authors:  A Catalano; G L Vita; M Russo; G Vita; A Lasco; N Morabito; S Messina
Journal:  Osteoporos Int       Date:  2016-09-02       Impact factor: 4.507

2.  Renal involvement in the pathogenesis of mineral and bone disorder in dystrophin-deficient mdx mouse.

Authors:  Eiji Wada; Takayuki Hamano; Isao Matsui; Mizuko Yoshida; Yukiko K Hayashi; Ryoichi Matsuda
Journal:  J Physiol Sci       Date:  2019-05-11       Impact factor: 2.781

Review 3.  Prevention and Treatment of Glucocorticoid-Induced Osteoporosis in Adults: Consensus Recommendations From the Belgian Bone Club.

Authors:  Michaël R Laurent; Stefan Goemaere; Charlotte Verroken; Pierre Bergmann; Jean-Jacques Body; Olivier Bruyère; Etienne Cavalier; Serge Rozenberg; Bruno Lapauw; Evelien Gielen
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-09       Impact factor: 6.055

4.  Bone and Muscle Pleiotropy: The Genetics of Associated Traits.

Authors:  Robert D Blank
Journal:  Clin Rev Bone Miner Metab       Date:  2014-02-18

5.  Bone health in Duchenne muscular dystrophy: clinical and biochemical correlates.

Authors:  Antonino Catalano; Gian Luca Vita; Federica Bellone; Maria Sframeli; Maria Grazia Distefano; Matteo La Rosa; Agostino Gaudio; Giuseppe Vita; Nunziata Morabito; Sonia Messina
Journal:  J Endocrinol Invest       Date:  2021-09-15       Impact factor: 4.256

6.  Bone health measured using quantitative ultrasonography in adult males with muscular dystrophy.

Authors:  C I Morse; J Smith; A Denny; J Tweedale; N D Searle; K Winwood; G L Onambele-Pearson
Journal:  J Musculoskelet Neuronal Interact       Date:  2016-12-14       Impact factor: 2.041

7.  Clinical and genetic characterisation of dystrophin-deficient muscular dystrophy in a family of Miniature Poodle dogs.

Authors:  Lluís Sánchez; Elsa Beltrán; Alberta de Stefani; Ling T Guo; Anita Shea; G Diane Shelton; Luisa De Risio; Louise M Burmeister
Journal:  PLoS One       Date:  2018-02-23       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.